Cocrystal Pharma
Open
$1.43
Prev. Close
$1.44
High
$1.43
Low
$1.43
Market Snapshot
$19.16M
-2.2
-1.73
11
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. The company is headquartered in Bothell, Washington and currently employs 11 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
emptyResult
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. The company is headquartered in Bothell, Washington and currently employs 11 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Recently from Cashu
Cocrystal Pharma Receives Fast Track Designation to Accelerate Innovative Therapy Development
Cocrystal Pharma Secures Fast Track Designation, Accelerating Development of Innovative Therapies Cocrystal Pharma has recently announced that it has received the FDA's Fast Track designation, marking…
Cocrystal Pharma: Summary of Recent Developments and Stock Insights
I apologize, but it seems that you have not provided the specific content for me to summarize. Could you please share the text you would like me to work with?
Cocrystal Pharma: Overview and Key Developments in Pharmaceutical Advancements.
Please provide the text you'd like me to summarize.
Cocrystal Pharma: Key Developments and Market Insights
Please provide the text you would like me to summarize, and I'll be happy to help!